Atrogi AB
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Metabolic Diseases
Atrogi is a Phase II-ready biotechnology company developing oral therapies that preserve and build functional muscle. Our lead compound, ATR-258, delivers healthy weight loss with improved muscle mass and function—directly addressing a critical limitation of GLP-1 therapies, where up to 45% of weight lost is lean mass rather than fat. Built on a proprietary "Third State" β2-receptor binding mechanism, ATR-258 avoids desensitization and enables chronic dosing without the cardiovascular liability and tremor of classic β2-agonists. With Phase I complete and strong safety and efficacy signals in hand, we are advancing two Phase 2a trials in healthy volunteers and obese patients on GLP-1s, measuring weight loss, muscle preservation, and muscle function. Our platform also enables expansion into rare muscle disorders and sarcopenia. Based in Stockholm and backed by Flerie Invest and Korea Investment Partners, we are raising $45M Series B to fund our Phase II program, with readouts in 2028.
Company HQ City:
Stockholm
Company HQ State:
Solna
Company HQ Country:
Sweden
Year Founded:
2013
Lead Product in Development:
ATR-258 – an oral, once-daily β2-receptor modulator for muscle-sparing weight loss. Phase I complete (SAD, MAD, 28-day T2D cohort) with strong safety and efficacy signals. Phase II ready, with two Phase 2a trials planned in healthy volunteers and obese patients on GLP-1 therapy.
CEO
Dr Paul Little
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
09/2026
What is your next catalyst (value inflection) update?
Muscle mass and function data from physiological efficacy trial in overweight individuals
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}